A new look at drugs targeting malignant melanoma-An application for mass spectrometry imaging-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A new look at drugs targeting malignant melanoma-An application for mass spectrometry imaging

Published:2014-08-18 Issue:17-18 Volume:14 Page:1963-1970
ISSN:1615-9853
Container-title:PROTEOMICS
language:en
Short-container-title:Proteomics

Author:

Sugihara Yutaka¹,Végvári Ákos²³,Welinder Charlotte¹,Jönsson Göran¹,Ingvar Christian⁴,Lundgren Lotta¹,Olsson Håkan¹,Breslin Thomas¹,Wieslander Elisabet¹,Laurell Thomas²,Rezeli Melinda²,Jansson Bo⁵,Nishimura Toshihide⁶,Fehniger Thomas E.²⁶,Baldetorp Bo¹,Marko-Varga György²⁶⁷

Affiliation:

1. Department of Oncology; Clinical Sciences; Lund University and Skåne University Hospital; Lund Sweden

2. Department of Biomedical Engineering; Clinical Protein Science & Imaging; Biomedical Center; Lund University; Lund Sweden

3. CREATE Health; Lund University; Lund Sweden

4. Department of Surgery; Clinical Sciences; Lund University; Lund Sweden

5. BioInvent Int. AB; Lund Sweden

6. Center of Excellence in Biological and Medical Mass Spectrometry; Lund University; Lund Sweden

7. First Department of Surgery; Tokyo Medical University; Tokyo Japan

Funder

Mrs. Berta Kamprad Foundation

Swedish Academy of Pharmaceutical Sciences

Swedish Research Council

Swedish Foundation for Strategic Research

Vinnova, Ingabritt & Arne Lundbergs forskningsstiftelse

Crafoord Foundation

Publisher

Wiley

Subject

Molecular Biology,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pmic.201300476/fullpdf

Reference55 articles.

1. Management of cutaneous melanoma;Tsao;N. Engl. J. Med.,2004

2. Final version of 2009 AJCC melanoma staging and classification;Balch;J. Clin. Oncol.,2009

3. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT;Blanke;J. Clin. Oncol.,2008

4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011

5. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma;Bollag;Nature,2010

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the antitumor activity of albendazole using Langmuir-Blodgett monolayers as surface mediated drug delivery system;International Journal of Pharmaceutics;2024-09

2. Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment;PROTEOMICS – Clinical Applications;2023-05-31

3. Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status;International Journal of Molecular Sciences;2023-03-07

4. Spatial Metabolomics Using Imaging Mass Spectrometry;Metabolomics;2023

5. Applications of mass spectroscopy in understanding cancer proteomics;Proteomics;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3